Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI Beverly Hills Rejuvenation Center Targeting the FOXO4 p53 axis by retro inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedeberg's Archives of Pharmacology Springer Nature Link 2022 Lupus Highlight Therapeutic Targeting of Senescent Cells in Lupus, Lupus Research Program, Congressionally Directed Medical Research Programs FOXO4 DRI (Proxofim) Selective Senescent Cell Disruption & Longevity Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols
product description
Why choose thelockerguy wholesale?
Show More
foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis